Medicus Pharma Ltd.
MDCX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.45
KIRA · Stoqly’s AI analyst, in plain words
- Medicus Pharma Ltd. had −$0.2M of revenue in fiscal 2025, down 877.2% on the year before.
- Its operating margin was 17,405.9%, up 61,425.2 pts: of every 100 in sales, about 17,406 is left after running the business.
- Medicus Pharma Ltd. lost $47.3M in fiscal 2025.
- Medicus Pharma Ltd. has $3.5M more cash than debt.
Market cap
$135M
P/E
—
Revenue
−$0.2M
Net income
−$47.3M
Free cash flow
—
Operating margin
17,405.9%
Medicus Pharma Ltd. in 30 seconds · fiscal 2025
Are sales growing?
−877.2%
No. Sales fell 877.2% last year.
Does it make a profit?
23,952.1%
No. It lost money last year.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Medicus Pharma Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- Medicus Pharma Ltd.
- CIK
- 0001997296
Medicus Pharma Ltd. · MDCX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | $0.0M | −$0.2M |
| Revenue growth | — | — | −877.2% |
| Net interest income | — | $0.0M | −$0.2M |
| Operating margin | — | −44,019.3% | 17,405.9% |
| Net income | −$5.3M | −$11.2M | −$47.3M |
| Net margin | — | −43,919.3% | 23,952.1% |
| Diluted EPS | −$1.53 | −$1.16 | −$2.74 |
| Cash | |||
| Cash from operations | −$4.2M | −$10.2M | −$22.8M |
| Share count change | — | 176.5% | 79.7% |
| Debt and strength | |||
| Cash and short-term investments | $1.7M | $4.2M | $8.7M |
| Debt incl. finance leases | — | $0.0M | $5.2M |
| Shareholders' equity | $1.1M | $3.1M | −$0.1M |
| Current ratio | 2.4x | 2.3x | 1.0x |
| Returns and quality | |||
| Return on equity | −478.2% | −525.4% | −3,083.1% |
| Return on tangible equity | −478.2% | −355.9% | — |
| Piotroski F-score | — | — | 1 |
| Altman Z'' | −42.0 | −25.1 | −43.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Medicus Pharma Ltd. · MDCX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.45 a share, the company is worth $135M.
Source: SEC EDGAR XBRL filings (CIK 0001997296). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.